loading
Precedente Chiudi:
$8.78
Aprire:
$8.84
Volume 24 ore:
192.92K
Relative Volume:
0.18
Capitalizzazione di mercato:
$1.38B
Reddito:
$61.10M
Utile/perdita netta:
$-138.36M
Rapporto P/E:
-6.8708
EPS:
-1.2
Flusso di cassa netto:
$-90.59M
1 W Prestazione:
-15.42%
1M Prestazione:
-26.21%
6M Prestazione:
+37.54%
1 anno Prestazione:
+283.11%
Intervallo 1D:
Value
$8.36
$8.88
Intervallo di 1 settimana:
Value
$8.43
$10.03
Portata 52W:
Value
$2.145
$11.78

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name
Nome
Ocular Therapeutix Inc
Name
Telefono
781-357-4000
Name
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Name
Dipendente
267
Name
Cinguettio
@OCUTX
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
OCUL's Discussions on Twitter

Confronta OCUL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
OCUL 8.36 1.38B 61.10M -138.36M -90.59M -1.20
VRTX 446.08 115.74B 10.63B -479.80M -1.35B 13.33
REGN 740.77 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.60 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.12 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.86 24.49B 3.30B -501.07M 1.03B 11.54

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-04-21 Iniziato Robert W. Baird Outperform
2022-08-10 Ripresa Berenberg Buy
2021-08-10 Aggiornamento H.C. Wainwright Neutral → Buy
2020-12-28 Downgrade H.C. Wainwright Buy → Neutral
2020-12-17 Iniziato Berenberg Buy
2020-11-13 Reiterato Raymond James Strong Buy
2020-08-10 Reiterato H.C. Wainwright Buy
2020-03-03 Aggiornamento Raymond James Outperform → Strong Buy
2019-05-21 Downgrade Cowen Outperform → Market Perform
2019-05-21 Reiterato H.C. Wainwright Buy
2019-05-21 Downgrade Raymond James Strong Buy → Outperform
2018-12-03 Reiterato Cantor Fitzgerald Overweight
2018-11-15 Iniziato Raymond James Strong Buy
2018-09-07 Iniziato Piper Jaffray Overweight
2017-10-24 Iniziato Guggenheim Buy
2017-07-26 Iniziato H.C. Wainwright Buy
2017-07-12 Reiterato Cantor Fitzgerald Overweight
2017-06-23 Downgrade Morgan Stanley Overweight → Equal-Weight
2017-02-10 Iniziato Cantor Fitzgerald Overweight
2016-11-15 Reiterato RBC Capital Mkts Outperform
2016-08-11 Iniziato JMP Securities Mkt Outperform
2016-02-17 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2015-10-23 Downgrade Morgan Stanley Overweight → Equal-Weight
2015-08-13 Iniziato Morgan Stanley Overweight
Mostra tutto

Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie

pulisher
Nov 20, 2024

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Ocular Therapeutix Q3 2024 Earnings Preview - MSN

Nov 20, 2024
pulisher
Nov 17, 2024

(OCUL) Technical Data - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 16, 2024

Ocular Therapeutix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Nov 16, 2024
pulisher
Nov 16, 2024

GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

Ocular Therapeutix Posts Mixed Third Quarter 2024 Results - Vision Monday

Nov 15, 2024
pulisher
Nov 14, 2024

Ocular Therapeutix: Q3 Earnings Snapshot - Houston Chronicle

Nov 14, 2024
pulisher
Nov 14, 2024

Ocular Therapeutix Reports Q3 2024 Financial Results - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Ocular Therapeutix Inc. (OCUL) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Acquires Significant Stake in Ocular Therapeutix Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Ocular Therapeutix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Ocular Therapeutix Inc earnings beat by $0.02, revenue fell short of estimates - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Ocular Therapeutix Inc Reports Q3 2024 Earnings: Revenue at $15. - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Q3 2024 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Ocular Therapeutix appoints Namrata Saroj as CBO - The Pharma Letter

Nov 14, 2024
pulisher
Nov 14, 2024

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Ocular Therapeutix Inc. Appoints Namrata Saroj, OD, as Chief Business Officer - Vision Monday

Nov 14, 2024
pulisher
Nov 13, 2024

A Peek at Ocular Therapeutix's Future Earnings - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnin - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Ocular Therapeutix™ to Present at the Jefferies London - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

Ocular Therapeutix appoints new Chief Business Officer By Investing.com - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Ocular Therapeutix appoints new Chief Business Officer - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer - The Manila Times

Nov 12, 2024
pulisher
Nov 07, 2024

Ocular Therapeutix (OCUL) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024 - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Rosalind Advisors Inc. Grows Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Ocular Therapeutix I - GuruFocus.com

Nov 05, 2024
pulisher
Nov 02, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 02, 2024
pulisher
Oct 28, 2024

Ocular Therapeutix stock soars to 52-week high of $11.64 By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

Ocular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year HighHere's What Happened - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Ocular Therapeutix stock soars to 52-week high of $11.64 - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Drops By 18.1% - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Assenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Oct 26, 2024
pulisher
Oct 21, 2024

Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR

Oct 21, 2024
pulisher
Oct 21, 2024

Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart

Oct 21, 2024
pulisher
Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024
pulisher
Oct 20, 2024

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - MSN

Oct 20, 2024
pulisher
Oct 20, 2024

HC Wainwright Reaffirms “Buy” Rating for Ocular Therapeutix (NASDAQ:OCUL) - Defense World

Oct 20, 2024
pulisher
Oct 18, 2024

SG Americas Securities LLC Purchases Shares of 45,187 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Ocular Therapeutix (NASDAQ:OCUL) Sets New 52-Week HighTime to Buy? - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Ocular Therapeutix stock soars to 52-week high of $11.34 - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Ocular Therapeutix stock soars to 52-week high of $11.34 By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load? - Simply Wall St

Oct 16, 2024

Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):